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Abstract: Our ability to evaluate residual stroke risk despite anticoagulation in atrial fibrillation
(AF) is currently lacking. The Calculator of Absolute Stroke Risk (CARS) has been proposed to
predict 1-year absolute stroke risk in non-anticoagulated patients. We aimed to determine whether
a modified CARS (mCARS) may be used to assess the residual stroke risk in anticoagulated AF
patients from ‘real-world’ and ‘clinical trial’ cohorts. We studied patient-level data of anticoagulated
AF patients from the real-world Murcia AF Project and AMADEUS clinical trial. Individual mCARS
were estimated for each patient. None of the patients were treated with non-vitamin K antagonist
oral anticoagulants. The predicted residual stroke risk was compared to actual stroke risk. 3503
patients were included (2205 [62.9%] clinical trial and 1298 [37.1%] real-world). There was wide
variation of CARS for each category of CHA2DS2-VASc score in both cohorts. Average predicted
residual stroke risk by mCARS (1.8 ± 1.8%) was identical to actual stroke risk (1.8% [95% CI, 1.3–2.4])
in the clinical trial, and broadly similar in the real-world (2.1 ± 1.9% vs. 2.4% [95% CI, 1.6–3.4]).
AUCs of mCARS for prediction of stroke events in the clinical trial and real-world were 0.678 (95%
CI, 0.598–0.758) and 0.712 [95% CI, 0.618–0.805], respectively. mCARS was able to refine stroke risk
estimation for each point of the CHA2DS2-VASc score in both cohorts. Personalised residual 1-year
absolute stroke risk in anticoagulated AF patients may be estimated using mCARS, thereby allowing
an assessment of the absolute risk reduction of treatment and facilitating a patient-centred approach
in the management of AF. Such identification of patients with high residual stroke risk could help
target more aggressive interventions and follow-up.
Keywords: atrial fibrillation; stroke risk; residual; anticoagulation; personalised; prediction tool
1. Introduction
Atrial fibrillation (AF) remains a major public health issue as it poses a significant risk
of stroke and mortality [1–3]. There are several elements to the management of patients
with AF, including regular and detailed risk assessments for stroke and bleeding [4].
These assessments are the cornerstone for enabling clinicians to provide appropriate
anticoagulation-related recommendations [5,6]. In this regard, the benefit of treatment must
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outweigh any potential risk. Furthermore, the patient-centred nature of AF management
dictates active communication of such information to patients during a shared-decision
making process [7].
To this end, numerous risk models are available to predict the stroke risk in AF [8,9].
Nevertheless, each of these was designed for using in a non-anticoagulated AF population
and intended to help classify patients in a dichotomous fashion (high vs. low risk) rather
than provide values of absolute risk. Hence, there is currently no validated model to predict
residual absolute stroke risk among anticoagulated patients with AF.
Recently, Lee et al. proposed the Calculator of Absolute Stroke Risk (CARS), which
provides an estimation of the personalised 1-year absolute risk of stroke [10]. The authors
studied this flexible risk-factor based model in a large ‘real-world’ Danish cohort of non-
anticoagulated patients with first-diagnosed AF, and found some advantages over the
widely used CHA2DS2-VASc score [8]. Although both models consist of similar clinical
components, CARS deals with the supplied information differently in that age is included
as a continuous variable and it takes into account the individual contribution of specific
risk factors, thereby requiring an online calculator [10]. The use of CARS in a clinical trial
cohort where stroke events are carefully adjudicated has not been previously described.
In this study, we aimed to determine whether a modified version of CARS may be used
to assess the residual stroke risk in anticoagulated patients with AF in real-world (Murcia
AF Project) and clinical trial (AMADEUS [Evaluating the Use of SR34006 Compared to
Warfarin or Acenocoumarol in Patients with Atrial Fibrillation] trial) cohorts.
2. Materials and Methods
For the present analysis, we included patients from the Murcia AF Project and
AMADEUS trial with a follow-up duration of 1-year or a stroke prior to this. The de-
sign of both studies have previously been described [11,12]. In brief, the Murcia AF Project
was an observational study from a tertiary hospital in Spain that enrolled consecutive
outpatients between May and December 2007 with non-valvular AF on stable vitamin
K antagonist (VKA) therapy (i.e., International Normalised Ratio [INR] of 2.0 to 3.0) in
the preceding six months. The initial period of stable INR minimised heterogeneity, thus
avoiding confounding factors due to differences in the quality of anticoagulation control at
study entry. The time in therapeutic range was re-calculated after six months. Patients with
a rheumatic mitral or prosthetic heart valve, as well as those with any acute coronary syn-
drome, stroke, haemodynamic instability, and hospital admission or surgical intervention
in the preceding six months were excluded.
The AMADEUS trial was a multicentre, randomised, open-label non-inferiority study
with blinded adjudication of outcomes comparing fixed-dose idraparinux vs. dose-adjusted
VKA in patients with non-valvular AF. Recruitment took place between September 2003
and July 2005. Patients with an indication for anticoagulation other than AF, transient AF
caused by a reversible disorder, active bleeding or high-risk of bleeding, creatinine clearance
of less than 10 mL/min, severe liver disease, uncontrolled hypertension, and recent or
anticipated invasive procedures with potential for uncontrolled bleeding were excluded.
A complete medical history was recorded at inclusion and the recorded parameters
were used to calculate the CHA2DS2-VASc score [8]. The 1-year absolute stroke risk
without anticoagulation was determined using the online CARS (https://hjerteforeningen.
shinyapps.io/riskvisrr/) [13]. Residual 1-year stroke risk with anticoagulation (‘mCARS’)
was estimated using prior evidence of a 64% risk reduction in treated patients [14]. In this
regard, mCARS was derived by multiplying the calculated CARS by 0.36.
In the Murcia AF Project, ischaemic stroke was defined as the sudden onset of a focal
neurological deficit in a location consistent with the territory of a major cerebral artery due
to an obstruction documented by imaging, surgery, or autopsy. All events in the AMADEUS
trial were adjudicated by a central committee, who were blinded to treatment assignment.
Events were limited to those that occurred within 1-year to enable a comparison between
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the risk of actual events and CARS, which was designed to estimate the 1-year absolute
stroke risk.
The study protocol of the Murcia AF Project was performed in accordance with the
ethical standards laid down in the 1964 Declaration of Helsinki and approved by the Ethics
Committee from University Hospital Morales Meseguer. De-identified patient level data
was used from the AMADEUS trial.
Statistical Analyses
Continuous baseline variables were expressed using median and interquartile range
(IQR), and tested for differences with Kruskal-Wallis test. Categorical variables were
expressed using absolute frequencies and percentages, and tested for differences using
chi-squared test.
Predicted 1-year stroke risks by CARS and CHA2DS2-VASc were compared using
Wilcoxon signed rank test. Actual stroke risk at 1-year was determined as a percentage
with 95% confidence intervals (CI). The predictive performance of mCARS for stroke events
was investigated using receiver-operating characteristic (ROC) curves, and tested against
the CHA2DS2-VASc score. Area under the curve (AUC) was used to reflect the c-index,
which represents the ability of scores to predict events. A two-sided p value of <0.05
was considered statistically significant. Analyses were performed using SPSS software
version 24.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc v. 16.4.3 (MedCalc Software bvba,
Ostend, Belgium).
3. Results
The study included 3503 patients with non-valvular AF: 2205 (62.9%) clinical trial
and 1298 (37.1%) real-world patients with a stable INR 6 months prior to recruitment.
Baseline demographics for the clinical trial cohort are summarised in Table S1. Median
age was 71 (IQR 65–77), with 34.6% females. The prevalence of hypertension, diabetes
mellitus, and prior thromboembolism were 75.9%, 19.5%, and 23.7%, respectively. Median
CHA2DS2-VASc score was 3 (IQR 2–4) with a distribution of: 1 (n = 178; 8.1%), 2 (n = 463;
21.0%), 3 (n = 572; 25.9%), 4 (n = 486; 22.0%), and ≥5 (n = 506; 22.9%). None of the patients
were treated with non-vitamin K antagonist oral anticoagulants.
Baseline demographics for the real-world cohort are summarised in Table S2. Median
age was 76 (IQR 70–81), with 51.8% females. The prevalence of hypertension, diabetes
mellitus, and prior thromboembolism were 81.7%, 26.1% and 4.1%, respectively. Median
CHA2DS2-VASc score was 4 (IQR 3–5) with a distribution of: 0 (n = 17; 1.3%), 1 (n = 66;
5.1%), 2 (n = 138; 10.6%), 3 (n = 270; 20.8%), 4 (n = 336; 25.9%), and ≥5 (n = 471; 36.3%).
In both cohorts, patients with increasing CHA2DS2-VASc score were significantly older
(p < 0.001 each) with greater comorbidities including anaemia (p < 0.001 each).
3.1. CARS, mCARS, and Actual Stroke Risk Based on CHA2DS2-VASc Score
The CARS, mCARS, and actual stroke risk at 1-year according to CHA2DS2-VASc score
was broadly similar across both the clinical trial and real-world cohorts (Table 1). Impor-
tantly, both CARS and mCARS increased with greater CHA2DS2-VASc score. Nonetheless,
there was a wide variation of CARS with extreme outliers for each category of CHA2DS2-
VASc score in both cohorts (Table 2).
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Table 1. CARS, mCARS, and actual stroke risk stratified by CHA2DS2-VASc score in clinical trials vs. the real-world.
Clinical Trial Real-World
CHA2DS2-
VASc CARS (IQR) mCARS (IQR)
Actual Stroke Risk
(95% CI) CARS (IQR) mCARS (IQR)
Actual Stroke Risk
(95% CI)
0 NA 0.9 (0.6–1.3) 0.3 (0.2–0.5) 0 (0–0)
1 1.1 (0.7–1.4) 0.4 (0.3–0.5) 0.6 (0–1.7) 1.4 (0.9–1.7) 0.5 (0.3–0.6) 0 (0–0)
2 2.0 (1.5–2.4) 0.7 (0.5–0.9) 0.9 (0–1.7) 2.1 (1.5–2.6) 0.8 (0.5–0.9) 1.4 (0.2–5.2)
3 2.6 (2.1–3.4) 0.9 (0.8–1.2) 0.9 (0.1–1.6) 2.8 (2.5–3.4) 1.0 (0.9–1.2) 1.5 (0.4–3.8)
4 3.6 (2.8–5.6) 1.3 (1.0–2.0) 2.7 (1.2–4.1) 3.9 (3.3–5.5) 1.4 (1.2–1.8) 3.0 (1.4–5.5)
5 6.7 (3.6–14.1) 2.4 (1.3–5.1) 3.1 (1.1–5.0) 4.8 (3.9–12.2) 1.7 (1.4–4.4) 2.6 (1.0–5.4)
6 13.6 (5.5–15.8) 4.9 (2.0–5.7) 2.2 (0–4.7) 12.8 (4.8–16.7) 4.6 (1.7–6.0) 4.0 (1.3–9.4)
7 15.7 (14.5–17.4) 5.7 (5.2–6.3) 1.7 (0–5.1) 15.6 (5.9–17.5) 5.6 (2.1–6.3) 3.4 (0.4–12.2)
8 16.5 (14.0–18.5) 5.9 (5.0–6.7) 28.6 (1.5–55.6) 16.9 (15.7–19.5) 6.1 (5.7–7.0) 5.9 (0.1–32.8)
9 17.7 (17.7–17.7) 6.4 (6.4–6.4) 0 (0–0) 11.1 (5.9–16.3) 4.0 (2.1–5.9) 0 (0–0)
CI, confidence interval; IQR, interquartile range; NA, not applicable.
Table 2. Range of absolute 1-year stroke risk stratified by CHA2DS2-VASc score in clinical trials vs.
the real-world.
Range of Absolute 1-Year Stroke Risk (%)
Clinical Trial Real-World
CHA2DS2-VASc score 0 NA 0.2–1.4
CHA2DS2-VASc score 1 0.2–2.0 0.2–13.0
CHA2DS2-VASc score 2 0.3–10.8 0.3–10.8
CHA2DS2-VASc score 3 0.4–13.3 0.9–13.3
CHA2DS2-VASc score 4 0.3–18.1 1.1–21.0
CHA2DS2-VASc score 5 1.9–20.9 1.2–21.0
CHA2DS2-VASc score 6 2.4–21.8 2.2–21.8
CHA2DS2-VASc score 7 4.5–21.9 4.1–23.5
CHA2DS2-VASc score 8 13.1–20.3 13.6–21.0
NA, not applicable.
3.2. Predicted 1-Year Stroke Risk by CARS vs. CHA2DS2-VASc
Predicted stroke risks by CARS and CHA2DS2-VASc were comparable in the clinical
trial (median CARS 2.9% [IQR 2.0–5.2] vs. CHA2DS2-VASc 3.2% [IQR 2.2–4.8], p = 0.794)
but not in the real-world (median CARS 3.8% [IQR 2.6–5.5] vs. CHA2DS2-VASc 4.8%
[IQR 3.2–7.2], p = 0.002 (Table 3). The upper limit of predicted stroke risk by CARS was
noticeably higher compared to CHA2DS2-VASc in both cohorts.
Table 3. Comparison of overall predicted 1-year stroke risk by CARS vs. CHA2DS2-VASc.
Clinical Trial Real-World
% Risk p value % Risk p value
CHA2DS2-VASc predicted stroke risk
Mean (SD) 4.3 (2.6) 5.3 (2.8)
Median (IQR) 3.2 (2.2–4.8) 4.8 (3.2–7.2)
Range 0.6–12.2 0.2–12.2
CARS predicted stroke risk
Mean (SD) 5.1 (4.9) 5.7 (5.2)
Median (IQR) 2.9 (2.0–5.2) 3.8 (2.6–5.5)
Range 0.2–21.9 0.794* 0.2–23.5 0.002*
IQR, interquartile range; SD, standard deviation. * CARS vs. CHA2DS2-VASc predicted stroke risk.
3.3. Predicted vs. Actual 1-Year Stroke Risk
At 1-year, there were 40 (1.8%) and 31 (2.4%) stroke events in the clinical trial and
real-world cohorts, respectively. The average predicted residual stroke risk by mCARS
(1.8 ± 1.8%) was identical to the actual risk of stroke events, despite anticoagulation (1.8%
[95% CI 1.3–2.4]) in the clinical trial and broadly similar in the real-world cohort (2.1 [±
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1.9%] by mCARS vs. 2.4% [95% CI 1.6–3.4]). Additionally, these values were comparable
across the various subgroups stratified by the CHA2DS2-VASc score in both cohorts.
Using ROC curve analyses, the AUC of mCARS and CHA2DS2-VASc score for predic-
tion of stroke events in the clinical trial cohort were similar, 0.678 (95% CI 0.598–0.758) and
0.673 (95% CI 0.591–0.754), respectively (Figure 1). Thus, the performance of both these
scores were not significantly different in the clinical trial cohort (p = 0.859).
Figure 1. Receiver-operating characteristic curves for 1-year stroke events by mCARS and CHA2DS2-
VASc score in the clinical trial (A) and real-world (B) cohorts.
In the real-world cohort, mCARS performed significantly better than the CHA2DS2-
VASc score for prediction of stroke events (AUC 0.712 [95% CI 0.618–0.805] vs. AUC 0.615
[95% CI 0.523–0.707], p = 0.001).
3.4. Exploratory Analysis
The distribution of mCARS based on the CHA2DS2-VASc score is shown in Figure 2.
In an exploratory analysis, we found that mCARS was able to refine stroke risk estimation
for each point of the CHA2DS2-VASc score in both clinical trial and real-world cohorts
(Table 4).
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Risk (95% CI), %
CHA2DS2-VASc score 0
NA
17 0 0 (0–0)
mCARS <1% 17 0 0 (0–0)
mCARS 1–2% 0 0 NA
mCARS 2–5% 0 0 NA
mCARS >5% 0 0 NA
CHA2DS2-VASc score 1 178 1 0.6 (0–1.7) 66 0 0 (0–0)
mCARS <1% 178 1 0.6 (0–1.7) 65 0 0 (0–0)
mCARS 1–2% 0 0 NA 0 0 NA
mCARS 2–5% 0 0 NA 1 0 0 (0–0)
mCARS >5% 0 0 NA 0 0 NA
CHA2DS2-VASc score 2 463 4 0.9 (0–1.7) 138 2 1.4 (0.2–5.2)
mCARS <1% 389 4 1.0 (0–2.0) 121 2 1.7 (0.2–6.0)
mCARS 1–2% 54 0 0 (0–0) 14 0 0 (0–0)
mCARS 2–5% 20 0 0 (0–0) 3 0 0 (0–0)
mCARS >5% 0 0 NA 0 0 NA
CHA2DS2-VASc score 3 572 5 0.9 (0.1–1.6) 270 4 1.5 (0.4–3.8)
mCARS <1% 303 2 0.7 (0–1.6) 107 0 0 (0–0)
mCARS 1–2% 200 2 1.0 (0–2.4) 153 4 2.6 (0.7–6.7)
mCARS 2–5% 69 1 1.4 (0–4.3) 10 0 0 (0–0)
mCARS >5% 0 0 NA 0 0 NA
CHA2DS2-VASc score 4 486 13 2.7 (1.2–4.1) 336 10 3.0 (1.4–5.5)
mCARS <1% 91 1 1.1 (0–3.3) 44 1 2.3 (0.06–12.7)
mCARS 1–2% 275 6 2.2 (0.4–3.9) 229 7 3.1 (1.2–6.3)
mCARS 2–5% 101 4 4.0 (0.1–7.8) 48 2 4.2 (0.5–15.0)
mCARS >5% 19 2 10.5 (0–25.7) 15 0 0 (0–0)
CHA2DS2-VASc score 5 295 9 3.1 (1.1–5.0) 269 7 2.6 (1.0–5.4)
mCARS <1% 16 0 0 (0–0) 16 0 0 (0–0)
mCARS 1–2% 128 4 3.1 (0.1–6.2) 153 1 0.7 (0.01–3.6)
mCARS 2–5% 76 3 3.9 (0–8.4) 45 1 2.2 (0.06–12.4)
mCARS >5% 75 2 2.7 (0–6.4) 55 5 9.1 (3.0–21.2)
CHA2DS2-VASc score 6 137 3 2.2 (0–4.7) 124 5 4.0 (1.3–9.4)
mCARS <1% 3 0 0 (0–0) 1 0 0 (0–0)
mCARS 1–2% 34 1 2.9 (0–8.9) 42 0 0 (0–0)
mCARS 2–5% 37 0 0 (0–0) 25 0 0 (0–0)
mCARS >5% 63 2 3.2 (0–7.6) 56 5 8.9 (2.9–20.8)
CHA2DS2-VASc score 7 59 1 1.7 (0–5.1) 59 2 3.4 (0.4–12.2)
mCARS <1% 0 0 NA 0 0 NA
mCARS 1–2% 2 0 0 (0–0) 13 0 0 (0–0)
mCARS 2–5% 10 0 0 (0–0) 9 0 0 (0–0)
mCARS >5% 47 1 2.1 (0–6.4) 37 2 5.4 (0.7–19.5)
CHA2DS2-VASc score 8 14 4 28.6 (1.5–55.6) 17 1 5.9 (0.1–32.8)
mCARS <1% 0 0 NA 0 0 NA
mCARS 1–2% 0 0 NA 0 0 NA
mCARS 2–5% 4 0 0 (0–0) 2 0 0 (0–0)
mCARS >5% 10 4 40.0 (3.1–76.9) 15 1 6.7 (0.2–37.1)
CHA2DS2-VASc score 9 1 0 0 (0–0) 2 0 0 (0–0)
mCARS <1% 0 0 NA 0 0 NA
mCARS 1–2% 0 0 NA 0 0 NA
mCARS 2–5% 0 0 NA 1 0 0 (0–0)
mCARS >5% 1 0 0 (0–0) 1 0 0 (0–0)
CI, confidence interval; NA, not applicable.
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Figure 2. mCARS vs. CHA2DS2-VASc score in clinical trials and the real-world.
4. Discussion
In this study of patients with AF, we demonstrated that: (1) there was considerable
variation in the predicted stroke risk by CARS for each category of the CHA2DS2-VASc
score; (2) the residual stroke risk determined by mCARS closely resembled the number
of stroke events despite anticoagulation; and (3) mCARS was superior to the CHA2DS2-
VASc score for predicting the residual stroke risk despite anticoagulation therapy, in the
real-world cohort. However, the predictive performance of both these scores were not
significantly different in the clinical trial cohort with adjudicated stroke events.
Our findings provide a means to quantify the absolute risk reduction offered by
anticoagulation therapy among individuals with AF, in everyday clinical practice. In this
regard, the absolute risk reduction may be derived from a simple comparison between
CARS (pre-anticoagulation risk) and mCARS (post-anticoagulation risk) to provide an
accurate marker for evaluating the benefit of specific treatments in AF. In daily practice,
stroke risk is estimated using the CHA2DS2-VASc score and weighed against the estimated
bleeding risk associated with anticoagulation therapy, in order to determine the optimal
treatment for patients with AF. However, this approach assumes that anticoagulation
will completely nullify any stroke risk, which is not true [15]. While this risk is reduced
by anticoagulation, some patients may still remain at disproportionately high risk of
residual stroke. These patients may be identified using mCARS for more aggressive
interventions, such as catheter ablation [16,17] and adherence to the ABC pathway [18],
and close follow-up.
Given the increasing treatment options and potential hazards associated with each [19–22],
both CARS and mCARS may be useful to assist in the clinician-patient communication of
stroke risk and the benefits of anticoagulation in AF. In this sense, a detailed discussion
centred on absolute risk (as offered by CARS and mCARS) will be more readily appreciable
by patients compared to relative risk, which has a tendency to exaggerate the perception of
difference [23].
For research purposes, mCARS provides a reliable method for estimating residual
stroke risk despite anticoagulation. This is particularly applicable to single-arm studies
that focus on alternative methods of stroke prevention in AF [24], as it allows the stroke
risk following intervention to be compared to estimated risk if anticoagulation therapy
had been utilised instead. Furthermore, with increasing evidence of the benefits of catheter
ablation in AF [25–28], this tool may be used to identify patients with a high residual stroke
risk despite anticoagulation, who may benefit from more aggressive treatment (and follow-
up). Importantly, we have shown that mCARS remains broadly valid in the context of both
clinical trial and real-world cohorts, although in terms of stroke prediction, the performance
of mCARS was similar to the CHA2DS2-VASc score, if based on the adjudicated outcomes
of a clinical trial cohort. A possible explanation for this lack of difference may be related
to the age of clinical trial participants, which were close to the cut-off thresholds of the
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CHA2DS2-VASc score, and therefore accounted for by this model. Alternatively, mCARS
may perform better in the real-world, given that it was derived from CARS, which was
designed using real-world data.
Overall the CHA2DS2-VASc score remains a valuable clinical asset, providing useful
information on stroke risk in a simplified and practical manner. The strength of this
approach lies in its ability to identify low-risk patients who may not derive net benefit
from anticoagulation therapy [8]. However, the wide variability of individual stroke
risk in each category of the CHA2DS2-VASc score, shown in this study, highlights the
simple reductionist nature of this clinical score. Indeed, mCARS was able to refine stroke
risk estimation for each point of the CHA2DS2-VASc score. Also, the components of the
CHA2DS2-VASc score do not carry equal weight for stroke, and also change differentially
over time [29,30]. The advantage of CARS is that it addresses some of these issues and
emphasises the point that stroke risk in AF is a continuum. It may further add to the
holistic and individualised management of patients with AF. Nevertheless, its calculation
is complex and may not be suitable for busy clinical settings.
Limitations
Given that the findings from this study were based on a post-hoc analysis of the
AMADEUS trial and a single-centre Caucasian population in the Murcia AF Project, it
should therefore be interpreted with caution and may not be representative of the wider
cohort of AF patients. There were no patients who were treated with a non-vitamin K
antagonist oral anticoagulant in this study. Nonetheless, the results remain pertinent as
VKA therapy is still used widely, especially in certain population groups such as those with
severe chronic kidney disease. Furthermore, as patients from the Murcia AF Project were
required to have a stable INR prior to enrolment, the findings from this study may be more
transferable to patients on non-vitamin K antagonist oral anticoagulant. As we censored
the outcomes at one year, it remains unclear whether our results would be applicable
to periods of extended follow-up. However, both the AMADEUS trial and Murcia AF
Project enrolled patients with a variety of stroke risk factors, which is reflected by the wide
distribution of CHA2DS2-VASc score, thereby strengthening the validity of mCARS as
a useful tool in AF. In determining mCARS, the relative risk reduction of anticoagulation
therapy was assumed to be constant across the whole cohort.
5. Conclusions
A personalised residual 1-year absolute risk of stroke in anticoagulated patients
with AF may be estimated using mCARS. This allows an assessment of the absolute risk
reduction of treatment and facilitates a patient-centred approach in the management of
AF. Such identification of patients with high residual stroke risk could help target more
aggressive interventions and follow-up.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10153357/s1, Table S1: Baseline characteristics stratified by the CHA2DS2-VASc score
in clinical trials, Table S2: Baseline characteristics stratified by the CHA2DS2-VASc score in the
real-world.
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